Overall survival and long-term outcomes from the randomized, double-blind, placebo-controlled, phase III IMerge trial of imetelstat for lower-risk myelodysplastic syndromes

Valeria Santini; Rami S. Komrokji; Michael R. Savona; María Díez-Campelo; Pierre Fenaux; Mikkael A. Sekeres; Yazan F. Madanat; David Valcárcel; Anna Jonášová; Petra Belohlavkova; Tymara Berry; Souria Dougherty; Sheetal Shah; Qi Xia; Libo Sun; Ying Wan; Fei Huang; Faye Feller; Shyamala Navada; Amer M. Zeidan; Uwe Platzbecker

doi:10.3324/haematol.2026.301456

Letters to the Editor

Overall survival and long-term outcomes from the randomized, double-blind, placebo-controlled, phase III IMerge trial of imetelstat for lower-risk myelodysplastic syndromes

Valeria Santini
Rami S. Komrokji
Michael R. Savona
María Díez-Campelo
Pierre Fenaux
Mikkael A. Sekeres
Yazan F. Madanat
David Valcárcel
Anna Jonášová
Petra Belohlavkova
Tymara Berry
Souria Dougherty
Sheetal Shah
Qi Xia
Libo Sun
Ying Wan
Fei Huang
Faye Feller
Shyamala Navada
Amer M. Zeidan
Uwe Platzbecker

MDS Unit, Hematology, DMSC, University of Florence, AOUC, Florence

Moffitt Cancer Center, Tampa, FL

Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN

University Hospital of Salamanca, IBSAL, Universidad de Salamanca, Salamanca

Hôpital Saint-Louis, Université de Paris 7, Paris

Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL

Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX

Vall d’hebron Institute of Oncology (VHIO), Hospital Universitario Vall d'Hebron, Barcelona

1st Medical Department – Hematology, General Hospital, Prague, Czech Republic

4th Department of Internal Medicine – Haematology, Charles University Hospital, Hradec Kralove, Czech Republic

Geron Corporation, Foster City, CA

Yale School of Medicine and Yale Cancer Center, Yale University, New Haven, CT

National Center for Tumor Diseases (NCT), University Hospital Carl Gustav Carus, TU Dresden, Dresden

Haematologica Early view Sep 3, 2026 https://doi.org/10.3324/haematol.2026.301456

Abstract

Not available.

Figures & Tables

Article Information

Early view : Letters to the Editor

DOI

https://doi.org/10.3324/haematol.2026.301456

Published

2026-09-03

Published By

Ferrata Storti Foundation, Pavia, Italy

Print ISSN

0390-6078

Online ISSN

1592-8721

This work is licensed under a Creative Commons Attribution 4.0 International License.

Article Usage

Online Views

367

PDF Downloads

189

No Data

PlumX

Overall survival and long-term outcomes from the randomized, double-blind, placebo-controlled, phase III IMerge trial of imetelstat for lower-risk myelodysplastic syndromes

Abstract

Figures & Tables

Article Information

Article Usage

Download Citation

Navigate

For Authors

For Reviewers

For Advertisers

Education

Privacy

More